CSA Medical

CSA Medical, founded in 2004 and based in Lexington, MA, is pioneering a first-in-class interventional approach for Chronic Bronchitis (CB) with its RejuvenAir System. The device employs precise, bronchoscopically delivered cryospray to destroy dysfunctional airway cells while preserving the underlying extracellular matrix, aiming to restore normal mucociliary clearance. The company is in a critical late-stage clinical phase, with its SPRAY-CB trial actively recruiting across leading U.S. academic centers to demonstrate safety and efficacy. Success could position RejuvenAir as the first device to modify the disease pathology of CB, addressing a significant unmet need beyond symptomatic drug therapies.

Metered cryospray (liquid nitrogen) delivered via bronchoscopy to ablate diseased airway epithelium while preserving the extracellular matrix to promote regeneration of healthy cells.

Direct competition is limited, as no other device is approved to treat the underlying pathology of Chronic Bronchitis. The system competes indirectly with escalating pharmaceutical regimens (bronchodilators, steroids, PDE4 inhibitors) and mucolytic agents, which only manage symptoms. Other bronchoscopic lung volume reduction devices target emphysema, a different COPD phenotype.